This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES Europe: Oligonucleotide and Peptide Therapeutics

SAVINGS DEADLINE EXPIRES:

  • 00
    Days
  • 00
    Hrs
  • 00
    Mins
  • 00
    Secs
Delivered as Hybrid Event from 16-18 November 2022
Live In-Person Conference Delivered 16-18 NovemberAustria Center Vienna

Perry Calias, PhD
Chief Operating Officer at Revolo Biotherapeutics

Profile

Dr. Calias brings over 30 years of biopharmaceutical experience in clinical development across the drug and device sectors of healthcare. His strengths include pre-clinical, clinical development and global regulatory submissions. Dr. Calias has extensive experience in CNS and neurology as well as rare diseases. He has a strong track record in compound development and pipeline progression, as well as building research and development organizations. He is currently the Chief Operating Officer for Revolo Biotherapeutics, responsible for all products development, CMC, Regulatory, Toxicology and Quality.  His previous experience includes serving as Chief Scientific Officer at Cerecor and Vice President of Global CMC and Product Development at Sucampo. He has held a variety of research and development positions both in clinical and non-clinical roles of expanded leadership at Pharming, Shire HGT Eyetech, Draper Labs and Genzyme.

Dr. Calias' strong background in early-stage asset development, as well as his clinical trial experience, as the ZEA Bioscience organization enters Phase 1 trials for our Hemophilia programs.

Dr. Calias obtained his Ph.D. in Bio-Organic Chemistry from Tufts University and his B.S. in biology from Suffolk University.

Agenda Sessions

  • Resetting the Immune System without Shutting it Down

    14:00